Assessment of Neuroendocrine Changes and Hypothalamo-Pituitary Autoimmunity in Patients with COVID-19
Thieme. All rights reserved..
SARS-CoV-2 may affect the hypothalamic-pituitary axis and pituitary dysfunction may occur. Therefore, we investigated neuroendocrine changes, in particular, secondary adrenal insufficiency, using a dynamic test and the role of autoimmunity in pituitary dysfunction in patients with COVID-19. The single-center, prospective, case-control study included patients with polymerase chain reaction (PCR)-confirmed COVID-19 and healthy controls. Basal hormone levels were measured, and the adrenocorticotropic hormone (ACTH) stimulation test was performed. Antipituitary (APA) and antihypothalamic antibodies (AHA) were also determined. We examined a total of 49 patients with COVID-19 and 28 healthy controls. The frequency of adrenal insufficiency in patients with COVID-19 was found as 8.2%. Patients with COVID-19 had lower free T3, IGF-1, and total testosterone levels, and higher cortisol and prolactin levels when compared with controls. We also demonstrated the presence of APA in three and AHA in one of four patients with adrenal insufficiency. In conclusion, COVID-19 may result in adrenal insufficiency, thus routine screening of adrenal functions in these patients is needed. Endocrine disturbances in COVID-19 are similar to those seen in acute stressful conditions or infections. Pituitary or hypothalamic autoimmunity may play a role in neuroendocrine abnormalities in COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme - 54(2022), 3 vom: 10. März, Seite 153-161 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gonen, Mustafa Sait [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3XMK78S47O |
|---|
| Anmerkungen: |
Date Completed 15.03.2022 Date Revised 15.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/a-1764-1260 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338075496 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338075496 | ||
| 003 | DE-627 | ||
| 005 | 20231225235842.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/a-1764-1260 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1126.xml |
| 035 | |a (DE-627)NLM338075496 | ||
| 035 | |a (NLM)35276740 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gonen, Mustafa Sait |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessment of Neuroendocrine Changes and Hypothalamo-Pituitary Autoimmunity in Patients with COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2022 | ||
| 500 | |a Date Revised 15.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thieme. All rights reserved. | ||
| 520 | |a SARS-CoV-2 may affect the hypothalamic-pituitary axis and pituitary dysfunction may occur. Therefore, we investigated neuroendocrine changes, in particular, secondary adrenal insufficiency, using a dynamic test and the role of autoimmunity in pituitary dysfunction in patients with COVID-19. The single-center, prospective, case-control study included patients with polymerase chain reaction (PCR)-confirmed COVID-19 and healthy controls. Basal hormone levels were measured, and the adrenocorticotropic hormone (ACTH) stimulation test was performed. Antipituitary (APA) and antihypothalamic antibodies (AHA) were also determined. We examined a total of 49 patients with COVID-19 and 28 healthy controls. The frequency of adrenal insufficiency in patients with COVID-19 was found as 8.2%. Patients with COVID-19 had lower free T3, IGF-1, and total testosterone levels, and higher cortisol and prolactin levels when compared with controls. We also demonstrated the presence of APA in three and AHA in one of four patients with adrenal insufficiency. In conclusion, COVID-19 may result in adrenal insufficiency, thus routine screening of adrenal functions in these patients is needed. Endocrine disturbances in COVID-19 are similar to those seen in acute stressful conditions or infections. Pituitary or hypothalamic autoimmunity may play a role in neuroendocrine abnormalities in COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Testosterone |2 NLM | |
| 650 | 7 | |a 3XMK78S47O |2 NLM | |
| 650 | 7 | |a Insulin-Like Growth Factor I |2 NLM | |
| 650 | 7 | |a 67763-96-6 |2 NLM | |
| 650 | 7 | |a Adrenocorticotropic Hormone |2 NLM | |
| 650 | 7 | |a 9002-60-2 |2 NLM | |
| 650 | 7 | |a Prolactin |2 NLM | |
| 650 | 7 | |a 9002-62-4 |2 NLM | |
| 650 | 7 | |a Hydrocortisone |2 NLM | |
| 650 | 7 | |a WI4X0X7BPJ |2 NLM | |
| 700 | 1 | |a De Bellis, Annamaria |e verfasserin |4 aut | |
| 700 | 1 | |a Durcan, Emre |e verfasserin |4 aut | |
| 700 | 1 | |a Bellastella, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Cirillo, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Scappaticcio, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Longo, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a Bircan, Basak Ecem |e verfasserin |4 aut | |
| 700 | 1 | |a Sahin, Serdar |e verfasserin |4 aut | |
| 700 | 1 | |a Sulu, Cem |e verfasserin |4 aut | |
| 700 | 1 | |a Ozkaya, Hande Mefkure |e verfasserin |4 aut | |
| 700 | 1 | |a Konukoglu, Dildar |e verfasserin |4 aut | |
| 700 | 1 | |a Kartufan, Fatma Ferda |e verfasserin |4 aut | |
| 700 | 1 | |a Kelestimur, Fahrettin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme |d 1969 |g 54(2022), 3 vom: 10. März, Seite 153-161 |w (DE-627)NLM000081981 |x 1439-4286 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2022 |g number:3 |g day:10 |g month:03 |g pages:153-161 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/a-1764-1260 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2022 |e 3 |b 10 |c 03 |h 153-161 | ||